Hormonal Treatment Effect on Sexual Distress in Transgender Persons: 2-Year Follow-Up Data.


Journal

The journal of sexual medicine
ISSN: 1743-6109
Titre abrégé: J Sex Med
Pays: Netherlands
ID NLM: 101230693

Informations de publication

Date de publication:
01 2020
Historique:
received: 11 03 2019
revised: 27 09 2019
accepted: 05 10 2019
pubmed: 19 11 2019
medline: 21 10 2020
entrez: 19 11 2019
Statut: ppublish

Résumé

As far as we know, no studies to date have investigated the psychobiological correlates of sexual distress (SD) nor the impact of hormonal treatment (HT) on SD in transgender persons. To evaluate the psychobiological correlates of SD and assess the effects of HT on SD in transgender persons without gender-affirming surgery. A consecutive series of 301 transgender persons (160 transwomen and 141 transmen) was considered for the cross-sectional study, and a subset of 72 subjects was studied in a 2-year follow-up. A physical examination was performed. Blood samples were drawn for determination of cortisol levels. Subjects completed psychometric measures. During 2 years of HT, the evaluation of SD was prospectively repeated. Psychobiological correlates of SD in transgender population. Changes in SD during gender affirming hormonal treatment. Knowing how hormonal treatment influence SD will help care providers when counseling transgender people. To the authors' knowledge, this is the first study prospectively evaluating the impact of gender affirming hormonal treatment on sexual distress in transgender individuals. The main limitations are represented by the small size of the sample and the use of questionnaires validated only in the cisgender population. SD showed a positive correlation with body uneasiness (P < .0001) and with dissatisfaction toward gender-related body parts or shapes (all P < .05). In addition, SD correlated positively with general psychopathology (P < .0001), alexithymia, social anxiety, and humiliation scales (all P < .05). In transmen, SD was positively associated with autism levels (P < .005), as well as with cortisol levels (P < .02). A significant correlation between SD and perceived discrimination was observed in transwomen (P < .05). In transwomen, SD was positively associated with hair density and negatively with breast growth (both P < .05). Finally, in transmen, a negative correlation was found between SD and hair density (P < .05). When the impact of HT on SD was evaluated, a significant reduction of SD was observed across time in both transwomen and transmen (P = .001 and P = .01, respectively). The present results support the efficacy of HT in reducing SD in transgender persons. Ristori J, Cocchetti C, Castellini G, et al. Hormonal Treatment Effect on Sexual Distress in Transgender Persons: 2-Year Follow-Up Data. J Sex Med 2020;17:142-151.

Identifiants

pubmed: 31735612
pii: S1743-6095(19)31464-X
doi: 10.1016/j.jsxm.2019.10.008
pii:
doi:

Substances chimiques

Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-151

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Jiska Ristori (J)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Carlotta Cocchetti (C)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Giovanni Castellini (G)

Psychiatry Unit, Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy.

Marina Pierdominici (M)

Center for Gender Specific Medicine, Istituto Superiore di Sanità, Rome, Italy.

Agnese Cipriani (A)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Diletta Testi (D)

Department of Health Sciences, University of Florence, Florence, Italy.

Gioele Gavazzi (G)

Institute for Hospitalization and Healthcare (IRCCS) SDN, Naples, Italy.

Francesca Mazzoli (F)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Maddalena Mosconi (M)

Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.

Maria Cristina Meriggiola (MC)

University of Bologna-Faculty of Medicine, Bologna, Italy.

Emanuele Cassioli (E)

Psychiatry Unit, Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy.

Linda Vignozzi (L)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Valdo Ricca (V)

Psychiatry Unit, Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy.

Mario Maggi (M)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.

Alessandra D Fisher (AD)

Andrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy. Electronic address: afisher@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH